Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 126.96.36.199) - Pipeline Review, H2 2018
Summary Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 188.8.131.52) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Serine Protein Kinase ATM - Pipeline Review, H2 2018, outlays comprehensive information on the Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 220.127.116.11) - Serine Protein Kinase ATM is a serine/threonine protein kinase. It activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. It plays a role in replication-dependent histone mRNA degradation. It binds DNA ends. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 2 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Adenocarcinoma, Colorectal Cancer, Colorectal Tumor, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Herpetic Keratitis, Human Papillomavirus (HPV) Associated Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Solid Tumor and Squamous Cell Carcinoma.
Furthermore, this report also reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 22.214.171.124) - The report reviews Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 126.96.36.199) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 188.8.131.52) targeted therapeutics and enlists all their major and minor projects - The report assesses Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 184.108.40.206) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 220.127.116.11) targeted therapeutics
Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 18.104.22.168)Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 22.214.171.124) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
INTRODUCTION According to the World Health Organization, in a year, around 2 million to 3 million individuals suffer from various forms of skin cancers, across the globe. This type of cancer account for 33% of all the diagnosed tumors, globally. It is also worth highlighting that one in every five Americans is likely to...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan, and Biocon. The global HER2 inhibitors market is expected to grow from $5.98 billion in 2020 to $6.4 billion in 2021 at a compound annual growth rate (CAGR) of 7%....
Head and Neck Squamous Cell Carcinoma - Epidemiology Forecast to 2030 Summary Head and neck cancers (HNCs) are a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (ICD-10 code = C00-C06),; the salivary glands...
Pheochromocytoma (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Pheochromocytoma - Drugs In Development, 2021, provides an overview of the Pheochromocytoma (Oncology) pipeline landscape.Pheochromocytoma is a rare, usually non-cancerous...
Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028 Report Analysis & Data Highlights: • Rybrevant Patent Insight • Rybrevant Dosage & Price • Rybrevant Sales Forecast 2028: > USD 4 Billion • Rybrevant Role in NSCLC & Other Cancer Therapies • Rybrevant Structure...
The apheresis market was valued at approximately USD 1,639 million in 2020, and it is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period, 2021-2026. The apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma...
Anaplastic Astrocytoma (Oncology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Astrocytoma - Drugs In Development, 2021, provides an overview of the Anaplastic Astrocytoma (Oncology) pipeline landscape.Anaplastic astrocytoma is a...
Summary ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products.The company develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment, and monitoring of disease. Its product...
630 pages •
By Roots Analysis Private Ltd.
• Aug 2021
INTRODUCTION Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including...
The global nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.